News
Australian Investor Online - LCT beginning clinical trials
February 9, 2007
Living Cells Technologies limited has now received approval to
start a Phase1/2A clinical trial in Russia for its DiabeCell diabetes treatment.
The trials
are designed according to FDA guidelines and monitored
by a Boston based Contract Research Organisation.
DiabeCell is a pig pancreatic cell product for the treatment of insulin dependent Diabetes.
The natural neo-natal pig islet cells are encased
in capsules that allow insulin to be
released but prevent the patient’s immune system from attacking the cells. The islets are simply
injected into the body and produce insulin as needed in response to the levels
of glucose in the
blood. This mimics the normal insulin release that occurs in healthy non-diabetic people and thus
helps regulate blood glucose levels in those suffering from type1 diabetes.
The trial may enable an expedited route to commercialization within the region. Initial response
to treatment will be evident within six months. The trial will use cells from fully screened and
biocertified pigs, bred according to United States FDA guidelines.
Click on the link below to access the full text:
Australian Investor Online article
|
